乌司他丁治疗老年重症急性胰腺炎伴发腹内高压31例临床研究  

Efficacy of Ulinastatin for Elderly Severe Acute Pancreatitis Complicating Intra- Abdominal Hypertension

作　　者：米忠友[1] 张春[1] 沈小春[2] 

机构地区：[1]武警重庆市总队医院,重庆400061 [2]中国人民解放军第三军医大学附属大坪医院,重庆400042

出　　处：《中国药业》2015年第8期27-29,共3页China Pharmaceuticals

摘　　要：目的探讨乌司他丁治疗老年重症急性胰腺炎(SAP)伴发腹内高压(IAH)患者的临床疗效。方法选取60岁以上SAP合并IAH患者62例,随机分为两组,各31例。两组患者均给予常规治疗,治疗组患者加用10万U乌司他丁,均治疗1周。于治疗前后测定患者腹内压(IAP)、肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-6)、血浆二胺氧化酶(DAO)、免疫球蛋白A(IgA)的水平,并评价其临床疗效。结果治疗组总有效率为93.55%,明显高于对照组的70.97%(P<0.05);治疗7 d后,两组患者的IAP,TNF-α,IL-6,DAO,IgA均较其治疗前有显著改善(P<0.05),治疗组改善幅度均显著大于对照组(P<0.05)。结论在常规治疗基础上加用乌司他丁治疗可提高老年SAP合并IAH患者的临床疗效,并可改善患者腹内压和肠黏膜的屏障功能。Objective To investigate the efficacy of ulinastatin for treating elderly severe acute pancreatitis（SAP） complicating intra- ab- dominal hypertension（IAH）. Methods 62 elderly patients （〉 60 years old）with SAP complicating IAH were randomly divided into two groups, 31 cases in each group. The control group was given the conventional treatment and the treatment group was additionally treated with 100 000 unit of ulinastatin per day. All patients were treated for 1 week. The clinical data were collected before and after treat- ment, including intra - abdominal pressure（IAP）, tumor necrosis factor - a（TNF - a）, interleukin（IL） - 6, plasma diamine oxidase（DAO）, immunoglobulin A（IgA）. The clinical effects of two groups were evaluated. Results The total effective rate of the treatment group was 93.55% ,which was significantly higher than 70.97% in the control group（P 〈 0. 05）. IAP,TNF-ct,IL-6,DAO and IgA after 7 d treatment in the two groups were significantly improved compared with those before treatment（ P 〈 0.05）. The ameliorative amplitude of those indexes in the treatment group was significantly higher than that in the control group（ P 〈 0. 05）. Conclusion Adding ulinastatin on the basis of conventional treatment can greatly improve the clinical effect of elderly SAP complicating IAH, and also improve the IAP and intestinal barrier function.

关 键 词：乌司他丁 重症急性胰腺炎 腹内高压 老年 

分 类 号：R969.4[医药卫生—药理学] R977.6[医药卫生—药学]